240 related articles for article (PubMed ID: 21167518)
21. Extended hepatic metastasectomy for renal cell carcinoma-new aspects in times of targeted therapy: a single-center experience over three decades.
Beetz O; Söffker R; Cammann S; Oldhafer F; Vondran FWR; Imkamp F; Klempnauer J; Kleine M
Langenbecks Arch Surg; 2020 Feb; 405(1):97-106. PubMed ID: 31938833
[TBL] [Abstract][Full Text] [Related]
22. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
23. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
24. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
25. The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma.
Bölükbas S; Kudelin N; Eberlein M; Fisseler-Eckhoff A; Schirren J
Thorac Cardiovasc Surg; 2012 Sep; 60(6):390-7. PubMed ID: 22207364
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
Keskin SK; Msaouel P; Hess KR; Yu KJ; Matin SF; Sircar K; Tamboli P; Jonasch E; Wood CG; Karam JA; Tannir NM
J Urol; 2017 Sep; 198(3):530-537. PubMed ID: 28411072
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Urol Oncol; 2021 Jan; 39(1):77.e17-77.e25. PubMed ID: 32863124
[TBL] [Abstract][Full Text] [Related]
28. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.
Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948
[TBL] [Abstract][Full Text] [Related]
29. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
[TBL] [Abstract][Full Text] [Related]
30. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
Tomita Y
Int J Urol; 2016 Jan; 23(1):13-21. PubMed ID: 26347163
[TBL] [Abstract][Full Text] [Related]
31. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Zaid HB; Parker WP; Safdar NS; Gershman B; Erwin PJ; Murad MH; Boorjian SA; Costello BA; Thompson RH; Leibovich BC
J Urol; 2017 Jan; 197(1):44-49. PubMed ID: 27473875
[TBL] [Abstract][Full Text] [Related]
32. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
33. Resection of pancreatic metastatic renal cell carcinoma: experience and long-term survival outcome from a large center in China.
Ma Y; Yang J; Qin K; Zhou Y; Ying X; Yuan F; Shi M; Jin J; Wang D; Gu J; Cheng D
Int J Clin Oncol; 2019 Jun; 24(6):686-693. PubMed ID: 30847618
[TBL] [Abstract][Full Text] [Related]
34. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.
Eggener SE; Yossepowitch O; Kundu S; Motzer RJ; Russo P
J Urol; 2008 Sep; 180(3):873-8; discussion 878. PubMed ID: 18635225
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic resection for metastases from renal cancer: long term outcome after surgery and immunotherapy approach - single center experience.
Gardini A; Morgagni P; Milandri C; Riccobon A; Ridolfi R; La Barba G; Saragoni L; Amadori D; Garcea D
Hepatogastroenterology; 2012 May; 59(115):687-90. PubMed ID: 22469709
[TBL] [Abstract][Full Text] [Related]
36. [Metastasectomy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors].
Firek P; Richter S; Jaekel J; Brehmer B; Heidenreich A
Urologe A; 2012 Mar; 51(3):398-402. PubMed ID: 22113553
[TBL] [Abstract][Full Text] [Related]
37. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
[TBL] [Abstract][Full Text] [Related]
38. The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study.
Dai J; He B; Zhang Y; Zhang H; Hu X; Xu L; Ni Y; Zhang X; Sun G; Zeng H; Shen P; Liu Z
World J Urol; 2024 Apr; 42(1):259. PubMed ID: 38662226
[TBL] [Abstract][Full Text] [Related]
39. Therapy of local recurrence of renal cell carcinoma.
Wiesner C; Jakse G; Rohde D
Oncol Rep; 2002; 9(1):189-92. PubMed ID: 11748481
[TBL] [Abstract][Full Text] [Related]
40. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
